Acorda Therapeutics , Inc. (NASDAQ: ACOR ) Q2 2014 Results Earnings Conference Call July 31, 2014 ..... Chen – Aegis Capital Presentation Operator Welcome to the Acorda Therapeutics Second Quarter 2014 Financial Results Conference Call
Acorda Therapeutics (NASDAQ: ACOR ) Q2 results : Net Revenues: $97.1M (+11.5%); Operating Expenses: $86.2M (+10.1%); Operating Income: $11
Acorda Therapeutics (NASDAQ: ACOR ): Q2 EPS of $0.42 Revenue of $97.13M (+11.6% Y/Y) beats by $5.73M . Press Release Post your comment!
AAWW , ABMD , ACIW , ACOR , ADP , AGI , ALKS , ALU , AMRC , APA , ASEI , ATK , AVP , AYR , AZN , BDX , BG , BGCP , BKCC , BLL , BUD , BWA , BZH , CCJ , CDW
this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks
BOSTON (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent on Thursday before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug...
EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared
exploring the possible sale of this business. Royalties on Acorda 's ACOR recently approved multiple sclerosis drug Ampyra will be key to EDT's future growth, and Acorda 's second-quarter results in August will give us a
research and development pipeline to support long - term growth . We're most optimistic about the potential of Ampyra ; Acorda ACOR received FDA approval for the novel MS drug in January , and Biogen has acquired international rights . We think Biogen
reduce the probability of a worst-case outcome in our scenario-weighted fair value estimate as a result. Acorda Therapeutics ACOR received FDA approval of Ampyra in January, and Biogen also filed for European approval of the drug last month